Hlee Lor, PharmD, BCPS

Donald G. Lamprecht Jr., PharmD, BCPS, CLS, FNLA

Payal Kohli, MD, FACC

Accredited by

American College of Cardiology

Course Description

Upon completion of this program, you should be able to:
- Recognize which statin-treated patients are at increased atherosclerotic cardiovascular disease (ASCVD) risk and identify if a patient is an appropriate candidate for icosapent ethyl.
- Discuss the benefit of icosapent ethyl in the management of ASCVD risk reduction.
- Identify the side effect profile for icosapent ethyl, as observed in the REDUCE-IT trial.

Activity Details

Credit Types:CME / MOC
Credit Amount:0.25 Credits
Release Date:2020-Jul-13
Expiration Date:2023-Jul-13
Registration Required:Yes

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.